Merck to acquire Prometheus for $10.8 billion to step up immunology presence
HQ Team April 17, 2023: US-based Merck will buy Prometheus Biosciences for about 10.8 billion to shore up its immunology portfolio to shield itself from.
Drugs
Pharma
Drugs
Health
Pharma
FDA applies brakes on Merck’s multiple sclerosis drug tests
HQ Team April 13, 2023: Merck KGaA announced the USFDA had put a hold on the initiation of new patients to test its.
Drugs
Pharma
Moderna-Merck’s cancer vaccine gets FDA breakthrough therapy designationÂ
Moderna Inc., a biotechnology company, and Merck announced that an experimental personalised cancer vaccine, based on the messenger RNA (mRNA) technology, has received.
Drugs
Medical
Pharma
Merck’s pill fails to prevent COVID-19 infection among households
Merck's COVID-19 pill does not stop the risk of prevention of the virus spreading to others in a household, the company stated.
Drugs
Medical
Pharma
PeptiDream bags over $3 billion in deals with Merck and Eli Lilly for delivering Novel Peptide Drug Conjugates
PeptiDream to collaborate with Merck and Eli Lilly for the discovery and development of Novel Peptide Drug Conjugates
Drugs
Medical
Pharma
Merck and Indonesia’s Bio Farma ink pact to produce HPV vaccine locally
Merck and Bio Farma of Indonesia sign deal to produce HPV vaccine for cervical cancer
Drugs
Pharma
Merck acquires Imago BioSciences for $1.35 billion
Merck, a US multinational pharmaceutical company, announced it would acquire Imago BioSciences for $1.35 billion.
Drugs
Pharma
Merck pays Moderna $250m for joint development of skin cancer vaccine
Moderna’s mRNA vaccine is being studied in combination with Merck’s Keytruda to treat patients with high-risk melanoma
Drugs
Pharma
Merck’s Covid-19 pill fails initial trial; AstraZenaca’s nasal spray too ineffective
Merck's Covid-19 pill no help in reducing hospitalization or death, Astrazenaca's nasal spray too fails trial